* BioLife Solutions Inc BLFS.OQ BLFS.O is expected
to show a
rise in quarterly revenue when it reports results on February
28.
* The Bothell Washington-based company is expected to
report a
143.2% increase in revenue to $35.813 million from $14.73
million a year ago, according to the mean estimate from 9
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for BioLife Solutions
Inc is
for a loss of 17 cents per share. For the same quarter last
year, the company reported a loss of 6 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for BioLife
Solutions
Inc is $64, about 62.8% above its last closing price
of $23.79.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2021 -0.09 -0.09 0.00 Beat 100
Jun. 30 2021 -0.09 -0.07 -0.12 Missed -80
Mar. 31 2021 -0.04 -0.04 -0.03 Beat 21.7
Dec. 31 2020 -0.02 -0.06 Missed -180
Sep. -0.01 -0.02 -0.08 Missed -336.4
30 2020
Jun. 30 2020 -0.03 -0.03 -0.70 Missed -1,900
Mar. 31 2020 0.01 -0.02 -0.01 Beat 38.5
Dec. 31 2019 -0.02 -0.02 0.02 Beat 205.9
This summary was machine generated February 26 at 03:01 GMT.
All figures in US dollars unless otherwise stated